CytoDyn Inc (OTCPK:CYDY)
$ 0.1351 -0.00065 (-0.48%) Market Cap: 143.01 Mil Enterprise Value: 172.09 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 32/100

Cytodyn Inc Dr. Pourhassan Discusses Citron Research's False Report Transcript

Jul 02, 2020 / NTS GMT
Release Date Price: $6.08 (-6.17%)
Christine Corrado
Proactive - Moderator

Hello, and welcome back to Proactive New York. I'm Christine Corrado. With me right now is Nader Pourhassan, CEO at CytoDyn. Nader, great to see you. How are you?

Nader Pourhassan
CytoDyn, Inc. - CEO

Great. Thanks for having me.

Christine Corrado
Proactive - Moderator

Nader, lots to talk about today. Let's first talk about this note that Citron Research put out. This is a notorious short seller. They basically put out a note that said the SEC must immediately halt this stock promotion scheme, all about CytoDyn. What's your response to that?

Nader Pourhassan
CytoDyn, Inc. - CEO

So I must say that we don't address these type of false allegation, but because our legal team believe this false report has resulted in unusual market activity or price variation. Therefore, I have been asked to briefly mention some of the false statement in this document.

In the first two sentences of this report, there were six false statement

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot